Compass Therapeutics (CMPX) Invested Capital (2023 - 2025)
Historic Invested Capital for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $209.6 million.
- Compass Therapeutics' Invested Capital rose 5145.67% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.6 million, marking a year-over-year increase of 5145.67%. This contributed to the annual value of $125.2 million for FY2024, which is 1568.96% down from last year.
- As of Q3 2025, Compass Therapeutics' Invested Capital stood at $209.6 million, which was up 5145.67% from $93.2 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Invested Capital peaked at $209.6 million during Q3 2025, and registered a low of $93.2 million during Q2 2025.
- Moreover, its 3-year median value for Invested Capital was $148.5 million (2023), whereas its average is $148.4 million.
- Examining YoY changes over the last 5 years, Compass Therapeutics' Invested Capital showed a top increase of 5145.67% in 2025 and a maximum decrease of 3620.5% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' Invested Capital stood at $148.5 million in 2023, then dropped by 15.69% to $125.2 million in 2024, then soared by 67.38% to $209.6 million in 2025.
- Its Invested Capital stands at $209.6 million for Q3 2025, versus $93.2 million for Q2 2025 and $110.3 million for Q1 2025.